On August 25, 2025, Zhonghong Biology celebrated its 14th anniversary. The "2025 Zhonghong Jingsen R&D Achievements Report Meeting & Annual R&D Department Mid-Year Assessment" was successfully held in the company's multi-function hall. All Zhonghong Jingsen employees gathered together, celebrating the company's birthday in the form of academic presentations and exchanges. Long-time supporters and leaders from relevant departments, as well as leaders from Qianhong Group and peers, also attended the meeting.

At the beginning of the meeting, President Ma Yong expressed his most sincere thanks to all employees for their hard work and to the board leaders and Qianhong peers for their long-standing care and guidance. On the occasion of Zhonghong Biology's 14th birthday, President Ma Yong required all employees to remember and practice the corporate original mission of "working for the needs of patient health," always bearing in mind the focus action principle of "not one, then not specialized; not specialized, then cannot"; and taking "prudence to the end as at the beginning" as the key construction keyword for 2025. He encouraged all employees to take vision and mission as the "end" and to strive for substantial creation and major breakthroughs as the "beginning," forging ahead to create new achievements.

From 2015 to 2025 was a decade of China's innovative drugs forging ahead and rapidly growing. We are grateful to be in the golden age of China's innovative drug development. At the same time, with the rapid development of artificial intelligence in recent years, the year of全民AI (AI for all) and 全行业AI (AI for all industries) has arrived. AI empowerment has permeated every aspect of the biopharmaceutical field, from innovative R&D to enterprise operations. Cognitive large models have brought new opportunities for the development of the medical and health field. President Ma proposed incorporating "AI + Biopharmaceuticals" into the company's development strategy, accelerating the construction of the AI empowerment innovation system platform to gain a competitive advantage in the fierce industry competition.

Subsequently, in the "Zhonghong Jingsen Annual Service Award" commendation session, President Ma presented plaques and awards to the employees who had stood the test of time with Zhonghong Jingsen.

The meeting entered its second agenda item. In the "Newcomer Forum" and "R&D Department Mid-Year Assessment," four R&D newcomers and 22 representatives from R&D teams and management departments reported on the progress of their respective R&D projects and the effectiveness of management platform construction. During the exchange session, attending guest leaders interacted constructively with the presenters, engaging in multi-dimensional discussions and explorations on the report content. The entire meeting was filled with a strong academic atmosphere, where different viewpoints intertwined and collided, achieving a perfect blend of academic rigor and critical thinking. After the presentations, the Zhonghong Jingsen Outstanding R&D Achievements Selection Committee held a review meeting. Based on the key evaluation principles of "innovativeness, completion degree, and growth potential," and focusing on "project breakthrough capability" and "project progress and completion quality," after strict and fair comprehensive review, two "2025 Zhonghong Jingsen Outstanding New R&D Talent Awards" and six "2025 Zhonghong Jingsen Outstanding R&D Achievement Awards" were ultimately selected. An award ceremony was held on-site.

At the end of the meeting, Chairman Wang Yaofang delivered a concluding speech. He highly affirmed the scientific and standardized management capabilities demonstrated by the Zhonghong Jingsen management team, their careful cultivation of various talents, and the corporate culture that fostered innovation and development. Chairman Wang called on all employees, standing at a critical node of the company's breakthrough development, to adhere to a rigorous and pragmatic, excellence-seeking fine style, fully leverage the role of backbone staff, actively embrace frontier knowledge, and skillfully use AI advanced tools to truly become value creators for the enterprise.

The original mission is like a torch, and the mission is like a blade. Fourteen years of working together, the Zhonghong Jingsen people have always harbored a passion and persistence for innovative drug R&D. We are still spirited, tenacious, and moving forward. Amid the host's heartfelt wishes and the audience's enthusiastic applause, the 2025 Zhonghong Jingsen R&D Achievements Report Meeting ended successfully. At the same time, all Zhonghong Jingsen people jointly experienced a fulfilling and unforgettable 14th-anniversary celebration, continuously improving over 14 years and embarking on a new journey steadily.

3. 江苏众红生物创立十二周年纪念活动暨2023众红京森研发成果报告会顺利举行‌

The 12th Anniversary Celebration of Jiangsu Zhonghong Biology and the 2023 Zhonghong Jingsen R&D Achievements Report Meeting was successfully held.

4. 2023年8月25日是众红生物创立十二周年的日子，“2023众红京森研发成果报告会暨年度研发部门中期考核”在众红生物多功能厅顺利举行...‌

On August 25, 2023, Zhonghong Biology celebrated its 12th anniversary. The "2023 Zhonghong Jingsen R&D Achievements Report Meeting & Annual R&D Department Mid-Year Assessment" was successfully held in the company's multi-function hall. All Zhonghong Jingsen employees gathered together, celebrating the company's birthday in the form of academic presentations and exchanges. Long-time supporters and leaders from relevant departments, as well as leaders from Qianhong Group and peers, also attended the meeting.

The first agenda item was President Ma Yong's speech and the 2023 "Zhonghong Jingsen Annual Service Award" commendation. President Ma Yong expressed the highest respect to the leaders and peers who have long cared for and guided Zhonghong Jingsen, and also conveyed his most sincere thanks to all employees of Zhonghong Jingsen for their companionship over the years. For 12 years since its establishment, the company has always placed the mission of solving unmet clinical needs first, consistently adhering to the original principle that "characteristic innovation is our only way to stand on our own." Facing the intensifying great power game and technological war, and the world's turbulent changes presenting new characteristics and trends, we have always adhered to a talent-strong enterprise and self-reliant development strategy with a bright prospect, firmly walking our own path and doing our own things well, maintaining strategic resilience with an adaptation strategy, taking "long-term" as the survival之道 for the company's healthy growth. In the past year, diversified product pipelines have been established in fields such as central nervous system drugs, cardio-cerebro-pulmonary vascular drugs, novel targeted anti-cancer drugs, and anti-allergy drugs, and multiple new drug projects have been completed for domestic and international registration applications. At the same time, efforts have been made to build a clinical medical research platform with Zhonghong characteristics, promoting the smooth implementation of Zhonghong's clinical research projects. President Ma proposed making "self-discipline, self-strengthening, self-confidence" the key construction keywords for 2023, encouraging everyone to persistently practice cultivating core competitiveness and deeply cultivating the corporate culture essence of "characteristic innovation source." He called on all Zhonghong Jingsen people to ride the waves together and not waste their youth. Additionally, President Ma announced the winners of the 2023 "Zhonghong Jingsen Annual Service Award" and conducted the plaque presentation and commendation ceremony.

The meeting entered its second agenda item. In the "Newcomer Forum" and "R&D Department Mid-Year Assessment," seven R&D newcomers and 18 representatives from R&D teams and management departments reported on the progress of their respective R&D projects and the effectiveness of management platform upgrades. On-site attending leaders and peers engaged in discussions and academic exchanges with the presenters during the Q&A session. The academic atmosphere at the meeting site was intense, with heated intellectual collisions. After the presentations, the Zhonghong Jingsen Outstanding R&D Achievements Selection Committee held a review meeting. Based on the three most critical evaluation principles of "innovativeness, completion degree, and growth potential," after strict and fair comprehensive review, two "2023 Zhonghong Jingsen Outstanding New R&D Talent Awards" and six "2023 Zhonghong Jingsen Outstanding R&D Achievement Awards" were ultimately selected, and an award ceremony was held on-site.

At the end of the meeting, Chairman Wang Yaofang delivered a speech. Chairman Wang pointed out in his speech that the future direction of China's pharmaceutical industry lies in continuous innovation, hoping that we can take innovation as our responsibility, continue to adhere to the path of characteristic innovation R&D, and continuously move forward to become better versions of ourselves.

Looking back on the journey, a thousand mountains are far away; looking ahead to the road ahead, ten thousand trees are springing up. Twelve years make a cycle, representing the cycle of life and renewal, symbolizing a brand new start. At the age of twelve, Zhonghong has always believed that dreams will become more magnificent due to constant forward strides, and success will always favor the determined, the enterprising, and the fighters. Amid the host's good wishes and the enthusiastic applause on-site, the 2023 Zhonghong Jingsen R&D Achievements Report Meeting came to a close, and all Zhonghong and Jingsen people jointly experienced a practical and unforgettable 12th-anniversary celebration.